{"id":232004,"date":"2026-09-04T16:41:54","date_gmt":"2026-09-04T11:11:54","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=232004"},"modified":"2026-09-04T16:41:57","modified_gmt":"2026-09-04T11:11:57","slug":"alivus-life-sciences-share-price-buy-hold-or-sell","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-buy-hold-or-sell\/","title":{"rendered":"Alivus Life Sciences: Should You Buy, Hold, or Sell Right Now?"},"content":{"rendered":"
<\/div>\n

Alivus Life Sciences share price Rs 1,379.10 (NSE), near its 52-week high. 52-week range Rs 819 to Rs 1,493.80. Q1 FY27 profit up 31.7% YoY to a record Rs 160.08 crore.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Alivus Life Sciences Ltd share price is trading around Rs 1,379, roughly 8 percent below its 52-week high of Rs 1,493.80 and more than 68 percent above its 52-week low of Rs 819. Q1 FY27 revenue grew 6.4 percent year on year to Rs 640.41 crore, with net profit up 31.7 percent to a record Rs 160.08 crore, the company’s highest-ever quarterly PAT. EBITDA margin expanded to 36.6 percent, driven by the non-GPL business now contributing 89 percent of revenue versus 75 percent a year earlier, even as the legacy GPL segment declined 52.6 percent due to inventory rationalization. The stock trades at 28.88 times earnings, a discount to the pharma sector average near 51.2 times.<\/p>\n<\/div>\n

Alivus Life Sciences share price is trading close to its 52-week high of Rs 1,493.80, with Alivus Life Sciences share price around Rs 1,379 on the NSE, more than 68 percent above its 52-week low of Rs 819. With a record profit quarter driven by strong margin expansion, investors are asking whether this API and CDMO maker is a stock to buy near its highs, a hold, or a sell.<\/p>\n

This Alivus Life Sciences stock analysis walks through the Q1 FY27 numbers, the shift toward the higher-margin non-GPL business, valuation against the pharma sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and investor communications.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n